Ana M Gonzalez-Angulo1, Ian Krop1, Argun Akcakanat1, Huiqin Chen1, Shuying Liu1, Yisheng Li1, Kirk S Culotta1, Emily Tarco1, Sarina Piha-Paul1, Stacy Moulder-Thompson1, Vivianne Velez-Bravo1, Aysegul A Sahin1, Laurence A Doyle1, Kim-Anh Do1, Eric P Winer1, Gordon B Mills1, Razelle Kurzrock1, Funda Meric-Bernstam2. 1. Departments of Breast Medical Oncology (AMGA, SL, SMT), Systems Biology (AMGA, GBM), Biostatistics (HC, YL, K-AD), Experimental Therapeutics (KSC), Investigational Cancer Therapeutics (AA, ET, SPP, VV-B, FMB), Pathology (AAS) and Surgical Oncology (FMB), The University of Texas MD Anderson Cancer Center, Houston, TX; Division of Hematology-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA (IK, EPW); Division of Hematology-Oncology, University of California, San Diego, CA (RK); Cancer Therapy Evaluation Program, NIH/National Cancer Institute, Rockville, MD (LAD). 2. Departments of Breast Medical Oncology (AMGA, SL, SMT), Systems Biology (AMGA, GBM), Biostatistics (HC, YL, K-AD), Experimental Therapeutics (KSC), Investigational Cancer Therapeutics (AA, ET, SPP, VV-B, FMB), Pathology (AAS) and Surgical Oncology (FMB), The University of Texas MD Anderson Cancer Center, Houston, TX; Division of Hematology-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA (IK, EPW); Division of Hematology-Oncology, University of California, San Diego, CA (RK); Cancer Therapy Evaluation Program, NIH/National Cancer Institute, Rockville, MD (LAD). fmeric@mdanderson.org.
Abstract
BACKGROUND: There is preclinical synergism between taxanes and MK-2206. We aim to determine the maximum tolerated dose, safety, and activity of combining MK-2206 and paclitaxel in metastatic cancer. METHODS: Patients received weekly doses of paclitaxel at 80mg/m2 on day 1, followed by MK-2206 orally on day 2 escalated at 90mg, 135mg, and 200mg. Treatment continued until progression, excessive toxicity, or patient request. Blood and tissue were collected for pharmacokinetic and pharmacodynamics markers. A cycle consisted of three weeks of therapy. Dose-limiting toxicity (DLT) was defined as unacceptable toxicity during the first cycle. All statistical tests were two-sided. RESULTS: Twenty-two patients were treated, nine in dose escalation and 13 in dose expansion. Median age was 55 years. Median number of cycles was four. Dose escalation was completed with no DLT. CTCAE Grade 3 or higher adverse events were fatigue (n = 2), rash (n = 2), hyperglycemia (n = 1), and neutropenia (n = 7). Four patients in the expansion phase required MK-2206 dose reduction. Phase II recommended dose was established as paclitaxel 80mg/m2 weekly on day 1, and MK-2206 135mg weekly on day 2. Paclitaxel systemic exposure was similar in the presence or absence of MK-2206. Plasma MK-2206 concentrations were similar to data from previous phase I monotherapy. There was a statistically significant decrease in expression of pAKT S473 (P = .01) and pAKT T308 (P = .002) after therapy. PI3K/AKT/mTOR downregulation in tumor tissues and circulating markers did not correlate with tumor response or clinical benefit. There were five objective responses, and nine patients had stable disease. CONCLUSION: MK-2206 was well tolerated with paclitaxel. Preliminary antitumor activity was documented.
BACKGROUND: There is preclinical synergism between taxanes and MK-2206. We aim to determine the maximum tolerated dose, safety, and activity of combining MK-2206 and paclitaxel in metastatic cancer. METHODS:Patients received weekly doses of paclitaxel at 80mg/m2 on day 1, followed by MK-2206 orally on day 2 escalated at 90mg, 135mg, and 200mg. Treatment continued until progression, excessive toxicity, or patient request. Blood and tissue were collected for pharmacokinetic and pharmacodynamics markers. A cycle consisted of three weeks of therapy. Dose-limiting toxicity (DLT) was defined as unacceptable toxicity during the first cycle. All statistical tests were two-sided. RESULTS: Twenty-two patients were treated, nine in dose escalation and 13 in dose expansion. Median age was 55 years. Median number of cycles was four. Dose escalation was completed with no DLT. CTCAE Grade 3 or higher adverse events were fatigue (n = 2), rash (n = 2), hyperglycemia (n = 1), and neutropenia (n = 7). Four patients in the expansion phase required MK-2206 dose reduction. Phase II recommended dose was established as paclitaxel 80mg/m2 weekly on day 1, and MK-2206 135mg weekly on day 2. Paclitaxel systemic exposure was similar in the presence or absence of MK-2206. Plasma MK-2206 concentrations were similar to data from previous phase I monotherapy. There was a statistically significant decrease in expression of pAKT S473 (P = .01) and pAKT T308 (P = .002) after therapy. PI3K/AKT/mTOR downregulation in tumor tissues and circulating markers did not correlate with tumor response or clinical benefit. There were five objective responses, and nine patients had stable disease. CONCLUSION:MK-2206 was well tolerated with paclitaxel. Preliminary antitumor activity was documented.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Lao H Saal; Karolina Holm; Matthew Maurer; Lorenzo Memeo; Tao Su; Xiaomei Wang; Jennifer S Yu; Per-Olof Malmström; Mahesh Mansukhani; Jens Enoksson; Hanina Hibshoosh; Ake Borg; Ramon Parsons Journal: Cancer Res Date: 2005-04-01 Impact factor: 12.701
Authors: Yoichi Nagata; Keng-Hsueh Lan; Xiaoyan Zhou; Ming Tan; Francisco J Esteva; Aysegul A Sahin; Kristine S Klos; Ping Li; Brett P Monia; Nina T Nguyen; Gabriel N Hortobagyi; Mien-Chie Hung; Dihua Yu Journal: Cancer Cell Date: 2004-08 Impact factor: 31.743
Authors: Howard H Bailey; Dona B Alberti; James P Thomas; Daniel L Mulkerin; Kimberly A Binger; Marco M Gottardis; Robert E Martell; George Wilding Journal: Clin Cancer Res Date: 2007-05-17 Impact factor: 12.531
Authors: A D Seidman; C A Hudis; J Albanell; J Albanel; W Tong; I Tepler; V Currie; M E Moynahan; M Theodoulou; M Gollub; J Baselga; L Norton Journal: J Clin Oncol Date: 1998-10 Impact factor: 44.544
Authors: Stefania Gori; Anna Maria Mosconi; Carlo Basurtol; Roberta Cherubinil; Verena De Angelis; Maurizio Tonato; Mariantonietta Colozza Journal: Tumori Date: 2002 Nov-Dec
Authors: K Kalinsky; J A Sparano; X Zhong; E Andreopoulou; B Taback; L Wiechmann; S M Feldman; P Ananthakrishnan; A Ahmad; S Cremers; A N Sireci; J R Cross; D K Marks; P Mundi; E Connolly; K D Crew; M A Maurer; H Hibshoosh; S Lee; D L Hershman Journal: Clin Transl Oncol Date: 2018-05-07 Impact factor: 3.405
Authors: A Jo Chien; Debasish Tripathy; Kathy S Albain; W Fraser Symmans; Hope S Rugo; Michelle E Melisko; Anne M Wallace; Richard Schwab; Teresa Helsten; Andres Forero-Torres; Erica Stringer-Reasor; Erin D Ellis; Henry G Kaplan; Rita Nanda; Nora Jaskowiak; Rashmi Murthy; Constantine Godellas; Judy C Boughey; Anthony D Elias; Barbara B Haley; Kathleen Kemmer; Claudine Isaacs; Amy S Clark; Julie E Lang; Janice Lu; Larissa Korde; Kirsten K Edmiston; Donald W Northfelt; Rebecca K Viscusi; Douglas Yee; Jane Perlmutter; Nola M Hylton; Laura J Van't Veer; Angela DeMichele; Amy Wilson; Garry Peterson; Meredith B Buxton; Melissa Paoloni; Julia Clennell; Scott Berry; Jeffrey B Matthews; Katherine Steeg; Ruby Singhrao; Gillian L Hirst; Ashish Sanil; Christina Yau; Smita M Asare; Donald A Berry; Laura J Esserman Journal: J Clin Oncol Date: 2019-02-07 Impact factor: 44.544